4- (1- (5- (3,4- dimethyl- 1H- pyrazol- 5- yl)- 2,4- dimethylbenzoyl)azetidin- 3- yl)benzonitrile

Fatty Acid Synthase, Type I inhibitor

Also Known As:

TVB 3166; TVB-3166; TVB3166

Networked: 6 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - 4-(1-(5-(3,4-dimethyl-1H-pyrazol-5-yl)-2,4-dimethylbenzoyl)azetidin-3-yl)benzonitrile: 6
  - Azetines
    - Azetidines: 6
      - 4-(1-(5-(3,4-dimethyl-1H-pyrazol-5-yl)-2,4-dimethylbenzoyl)azetidin-3-yl)benzonitrile: 6
Organic Chemicals: 133
- Nitriles: 227
  - 4-(1-(5-(3,4-dimethyl-1H-pyrazol-5-yl)-2,4-dimethylbenzoyl)azetidin-3-yl)benzonitrile: 6

Experts

1.	Kemble, George: 2 articles (08/2015 - 01/2015)
2.	Wang, Zhaoti: 2 articles (08/2015 - 01/2015)
3.	Alers, Victoria: 1 article (06/2021)
4.	Balinda, Henriette U: 1 article (06/2021)
5.	Brenner, Andrew J: 1 article (06/2021)
6.	Garcia, Michael: 1 article (06/2021)
7.	Gruslova, Aleksandra: 1 article (06/2021)
8.	Huang, Tim: 1 article (06/2021)
9.	McClellan, Bryan: 1 article (06/2021)
10.	Sareddy, Gangadhara R: 1 article (06/2021)

Related Diseases

1.	Neoplasms (Cancer) 08/01/2015 - "Our data demonstrate that selective and potent FASN inhibition with TVB-3166 leads to selective death of tumor cells, without significant effect on normal cells, and inhibits in vivo xenograft tumor growth at well-tolerated doses. " 08/01/2015 - "TVB-3166, an orally-available, reversible, potent, and selective FASN inhibitor induces apoptosis, inhibits anchorage-independent cell growth under lipid-rich conditions, and inhibits in-vivo xenograft tumor growth. " 06/01/2021 - "Additionally, TVB-3166 significantly inhibited tamoxifen-resistant breast tumor growth in mice and decreased proliferation of primary tumor explants compared to untreated controls. "
2.	Breast Neoplasms (Breast Cancer) 01/01/2022 - "Furthermore, treatment with the FASN inhibitor, TVB-3166, resulted in a decreased breast cancer cell survival and proliferation while increasing apoptosis upon sera exposure (BMI >30). " 06/01/2021 - "Our preclinical data provide evidence that FASN inhibition by TVB-3166 presents a promising therapeutic strategy for the treatment of endocrine-resistant breast cancer. " 06/01/2021 - "Additionally, TVB-3166 significantly inhibited tamoxifen-resistant breast tumor growth in mice and decreased proliferation of primary tumor explants compared to untreated controls. "
3.	Paramyxoviridae Infections (Parainfluenza) 01/01/2015 - "Further, TVB-3166 also inhibits the production of RSV B, human parainfluenza 3 (PIV3), and human rhinovirus 16 (HRV16) progeny from A549, HEp2 and HeLa cells respectively. "
4.	Prostatic Neoplasms (Prostate Cancer) 11/10/2020 - "Therefore, to confirm the metabolic alterations at the cellular level during FAS inhibition, we treated LNCaP-LN3 prostate cancer cells with FAS inhibitors (Fasnall, GSK2194069, and TVB-3166). "
5.	Infections 01/01/2015 - "In vivo, oral administration of TVB-3166 to RSV-A (Long)-infected BALB/c mice on normal chow, starting either on the day of infection or one day post-infection, reduces RSV lung titers 21-fold and 9-fold respectively. "

Related Drugs and Biologics

1.	Fatty Acid Synthases (Fatty Acid Synthase)
2.	Tamoxifen
3.	Lipids
4.	GSK2194069

Related Therapies and Procedures

1.	Oral Administration